Table 3.
Best overall response per RECIST V.1.1 across MMRD tumor sites
| Brain (n=8) | Colon (n=33) | Endometrium (n=29) | Gastric (n=8) | Small intestine (n=5) | Others (n=17) | All (n=100) | |
| ORR no. (%; 95% CI) | 0 (0.0; 0.0 to 0.0) | 14 (42; 24.6 to 60.2) | 13 (45; 25.6 to 60.2) | 3 (38; 0.0 to 80.7) | 5 (100; 100 to 100) | 7 (41; 15.1 to 67.3) | 42 (42; 32.2 to 51.8) |
| CR no. (%) | 0 (0.0) | 6 (18.2) | 4 (13.8) | 2 (25.0) | 1 (20.0) | 2 (11.7) | 15 (15.0) |
| PR no. (%) | 0 (0.0) | 8 (24.2) | 9 (31.0) | 1 (12.5) | 4 (80.0) | 5 (29.4) | 27 (27.0) |
| SD no. (%) | 1 (12.5) | 13 (39.4) | 8 (27.6) | 2 (25) | 0 (0.0) | 4 (23.5) | 28 (28.0) |
| PD no. (%) | 7 (87.5) | 6 (18.2) | 8 (27.6) | 3 (37.5) | 0 (0.0) | 6 (35.2) | 30 (30.0) |
CR, complete response; MMRD, mismatch repair-deficient; ORR, objective response rate; PD, progressive disease; PR, partial respose; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.